Uniquely Designed To Cut Down Cholesterol
Watch how LEQVIO works
The liver plays a key role in clearing bad cholesterol (LDL-C) from the blood, but certain proteins in the liver can interfere with this process. LEQVIO uses the body's natural processes to prevent many of these proteins from forming in the first place, cutting down bad cholesterol for up to 6 months per injection, after the two initial doses.
Talk to your health care provider to learn how LEQVIO works differently than other cholesterol-lowering treatments
LEQVIO Clinical Study Results
LEQVIO delivers effective and long-lasting reduction of bad cholesterol (LDL-C)
In a clinical study of people with known heart disease on a statin who needed more help lowering bad cholesterol (LDL-C), people given LEQVIO lowered their bad cholesterol by over 50% and kept it low during each 6-month dosing interval vs placebo (a substance that doesn't contain any medication).
Individual results may vary.
Clinical study information
These results are based on a study in which 1561 patients with atherosclerotic cardiovascular disease (ASCVD) were on a maximally tolerated statin with or without another cholesterol-lowering treatment—in addition to LEQVIO (781 patients) or a placebo (780 patients). Cholesterol levels were measured at the start of the study and compared with cholesterol levels 17 months later. Sixty percent of the patients were 65 years or older.
LEQVIO helped patients reach their goal
In a clinical study,
people taking LEQVIO + statin achieved the recommended cholesterol goal of <70 mg/dL vs 2 out of 10 people taking statin + placebo at 17 months
Works with your current statin
LEQVIO doesn't replace healthy food choices, regular physical activity, or a statin. Instead, it works with your statin to reduce your bad cholesterol even further.
Safety information from multiple studies
In 3 clinical studies with more than 3500 people, 1833 people were treated with LEQVIO and 1822 people were treated with placebo.
The most common side effects of LEQVIO were: injection site reaction (including pain, redness, and rash), joint pain, urinary tract infection, diarrhea, chest cold, pain in legs or arms and shortness of breath
Side effects leading to discontinuation occurred in 2.5% of people taking LEQVIO vs 1.9% with placebo
A guide to help you
navigate your next
conversation about Leqvio
Have questions for your health care provider? This
Doctor Discussion Guide can help you get the most out
of your appointment.
DOSING & ADMINISTRATION
Talk to your health care provider to see if two doses a year of
LEQVIO is right for you.*
*Two doses a year after two initial doses.